All News

In patients undergoing single-stage bulbar urethroplasty with buccal mucosa for urethral strictures, neither dorsal nor ventral onlay of the graft is inherently superior, data from a retrospective review suggest.

In a study identifying the risk of major birth defects associated with different types of assisted reproductive technology, Australian researchers have reported a significantly higher risk of birth defects involving intracytoplasmic sperm injection (ICSI) compared to in vitro fertilization (IVF).

Dean G. Assimos, MD, has been named the inaugural chair of the department of urology in the University of Alabama at Birmingham School of Medicine.

ProUroCare Medical Inc. (Minneapolis), has received FDA clearance to market its ProUroScan prostate mechanical imaging system.

About one-third of computed tomography scans performed following an inconclusive abdominal ultrasound examination have positive findings, according to a recent study. Follow-up scans appear to be most useful in the diagnosis of renal lesions.

Urodynamic studies conducted in women prior to stress urinary incontinence surgery may not be necessary, according to a multicenter study funded by the National Institutes of Health.

Patients with localized renal cell carcinoma treated with either partial nephrectomy or simple tumor enucleation have equivalent results in terms of local recurrence and cancer-specific survival after an estimated 10 years' follow-up.

As has happened throughout the field of medicine over the past decade, a growing number of urologists are merging to create larger, more expansive urology practices. Here's how one newly merged practice stayed on track during the merger process.

Urologists have just been hit with a solid left-right combination in a new round of the fight over self-referral. Within a month, they have had to counter two separate studies questioning their use of in-house pathology and radiology services.

Signs of the sea change to come in the treatment of interstitial cystitis/bladder pain syndrome (IC/BPS) will be part of the 2012 AUA annual meeting. Next year should bring even more, as the National Institute of Diabetes and Digestive and Kidney Diseases and pharma research get readied for meeting debuts.

Attendees of the 2012 AUA annual meeting can anticipate learning about studies of sexual dysfunction that may have a significant impact on treatment paradigms.

Holding property in joint tenancy with rights of survivorship (JTWROS) generally provides no asset protection. In fact, JTWROS ownership exposes the property to the creditors of each of the joint tenants.

The program on advanced prostate cancer at the 2012 AUA annual meeting will include maturing data from clinical trials investigating targeted and vaccine therapies, as well as some preliminary information suggesting that folate may have a chemopreventive effect.

While cost remains a concern, incorporating robotics into urologic laparoscopy appears to improve the experience for patients and physicians alike.

Outcomes for men with prostate cancer are strongly related to risk category according to clinical stage, Gleason score, and serum PSA, and there is a continuous risk of death from the disease up to 15 years after diagnosis.

The newest urology products and services from Olympus, Teleflex, Inc., Medline Industries, Inc., and Wiley-Blackwell.

Minimally invasive radical prostatectomy (MIRP), which encompasses laparoscopic and robot-assisted procedures, holds no advantage over open radical prostatectomy in terms of complication rates.

Observational data fail to support a role of 5-alpha-reductase inhibitors (5-ARIs) for secondary prevention of clinically significant prostate cancer in men with very low-risk disease.

There will always be a place for laboratory research in andrology, but the past year has been one of surgical advancements for those who diagnose and treat male infertility.

Low-dose computed tomography scans reduce radiation exposure while maintaining diagnostic quality in patients with stage I testicular germ cell tumors being managed with surveillance following orchiectomy.

Stone disease and minimally invasive treatment approaches are once again leading issues in the pediatric urology section of the 2012 AUA annual meeting.

This bonus "State of Urology" issue offers a sneak-peek at some of the outstanding research you'll learn more about at the AUA annual meeting in Atlanta.

The 2012 AUA annual meeting will reflect incremental progress occurring in the management of lower urinary tract symptoms (LUTS) secondary to BPH, as well as emerging information about the epidemiology and underlying biology of the disease process.

Dose titration of the vascular endothelial growth factor receptor inhibitor axitinib (Inlyta) to achieve therapeutic blood levels may be required for patients with metastatic renal cell carcinoma to derive optimal benefit from the drug as second-line therapy.

Several abstracts from this year's AUA annual meeting suggest that, just as bacteria alter their host environment to their benefit, treatments for infection and inflammation may counter by changing the host environment to pathogens' detriment.

Urologists agree that PSA screening will be the hot topic at the AUA annual meeting in Atlanta.

The FDA recently issued a complete response letter for Amgen Inc.'s supplemental Biologics License Application for the RANK ligand inhibitor denosumab (XGEVA) to treat men with castration-resistant prostate cancer at high risk of developing bone metastases.